InstalabLoading...
InstalabLoading...
Two people with the same weight and height can be in radically different shape. One can be muscular and metabolically resilient. The other can carry the same number on the scale but be quietly losing the lean tissue that protects against falls, surgery, infection, and chronic disease. FFMI (fat-free mass index) is the number that tells these two bodies apart.
FFMI takes everything in your body that is not fat, mainly muscle, organs, bone, and water, and indexes it to your height. Knowing this number gives you something BMI cannot: a direct read on whether you have enough lean tissue to age well, recover from illness, and stay strong through your fifties, sixties, and beyond.
FFMI is calculated as fat-free mass in kilograms divided by your height in meters squared. Fat-free mass is what is left when fat is subtracted from your total body weight. About half of it is skeletal muscle. The rest is internal organs, bones, connective tissue, and the water inside your cells.
Because FFMI ignores fat entirely, it gives a much cleaner picture of muscle reserves than weight or BMI. Two methods are commonly used to derive it: a DXA scan, which uses a low-dose x-ray to map tissue composition, and bioimpedance (BIA), which sends a tiny electrical current through your body and infers tissue makeup from how the current flows. BIA-derived FFMI tracks closely with DXA-based appendicular muscle mass measurements (correlation around 0.95 to 0.96 in a study of 1,313 adults).
Across very large cohorts, FFMI and closely related lean mass measures consistently predict who lives longer and who does not. The relationship often follows a curved shape: very low lean mass is dangerous, but extreme highs can also signal risk in some causes of death.
In a Taiwan-based cohort of 422,430 adults followed for about nine years, people in the lowest fifth of FFMI had roughly 14% higher all-cause mortality, and those in the highest fifth had roughly 16% higher all-cause mortality, compared to the middle group. For respiratory mortality, the pattern was strikingly linear: people in the lowest FFMI fifth were about 95% more likely to die from a respiratory cause, while those in the highest fifth were about 28% less likely.
In a U.S. cohort of about 38,000 men followed for over 21 years, lean body mass had a U-shaped relationship with all-cause death, with the second through fourth fifths showing roughly 8% to 10% lower mortality than the lowest. The protective signal for respiratory death was strong and consistent across all groups with adequate lean mass.
In chronic heart failure, low FFMI is one of the strongest non-cardiac predictors of bad outcomes. In a Japanese study of 267 heart failure patients followed about 11 months, each one-unit higher FFMI was linked to roughly 32% lower risk of cardiac death or heart failure rehospitalization.
Among 6,328 Israeli heart failure patients, those in the highest FFMI quartile had about 21% lower risk of death than the reference group. In a Chinese cohort of 4,305 heart failure patients, the lean body mass index quartile rankings tracked steadily with one-year survival: people in the highest quartile had roughly 39% lower mortality than those in the lowest, even after adjusting for standard risk factors.
A separate analysis of 60,335 adults at the Mayo Clinic, followed for an average of 15 years, found a different angle on the same biology: very high FFMI was associated with about 2.2 times higher cardiovascular mortality compared to those with medium FFMI. The takeaway is not that muscle is harmful but that FFMI rises with both healthy lean mass and unhealthy body size, so it has to be interpreted alongside fat mass.
Higher FFMI looks protective in heart failure but harmful in some general-population mortality data. Both can be true. FFMI captures everything that is not fat, including the muscle, organ, and water expansion that come with severe obesity. In sick patients losing muscle, more lean mass means more reserve. In otherwise healthy people, very high FFMI often goes with very high fat mass, which is what is driving the risk. FFMI is a body-composition signal, not a single good-or-bad number, and its meaning depends on what your fat mass is doing alongside it.
Low FFMI consistently predicts worse cancer survival, and it does so even when BMI looks reassuring. In a study of 1,602 cancer patients with normal or high BMI, low FFMI was linked to about 69% higher risk of death over follow-up. Patients with both low FFMI and ongoing weight loss had roughly 3.5 times the mortality risk of those with normal lean mass and stable weight.
In 656 colorectal cancer patients, those with a high FFMI-based cachexia index had about 53% lower five-year mortality than those with a low score. In 404 head and neck cancer patients, those who died within six months of starting treatment had pretreatment FFMI values around 17.6 kg/m² compared to 19.5 in survivors, a difference BMI did not reliably capture.
Low FFMI is one of the most consistent prognostic markers in chronic obstructive pulmonary disease (COPD). A meta-analysis pooling 17 studies found that COPD patients had significantly lower FFMI than controls, and within the COPD population, lower FFMI was strongly tied to higher mortality and more frequent acute exacerbations.
In a chest CT-based study of 3,880 COPD patients, low FFMI was an independent predictor of death. In COPD overlapping with sleep apnea, FFMI tracked with lung function, sleep quality, and exacerbation frequency, suggesting it captures systemic disease severity that purely respiratory tests miss.
The metabolic story is more nuanced. In a cross-sectional analysis of 10,085 U.S. adults, both higher FFMI and higher fat mass index were associated with higher odds of diabetes and prediabetes in a roughly linear pattern. Researchers attribute much of this signal to the fact that fat-free mass measurements include water and connective tissue that scale with weight gain, not pure muscle quality. In other words, FFMI alone cannot distinguish a 90-kg lean athlete from a 90-kg sedentary adult with high muscle and high ectopic fat. Pairing FFMI with fat mass index gives a much sharper read on metabolic risk.
FFMI is increasingly used as a screening tool for sarcopenia, the age-related loss of muscle that drives falls, fractures, and loss of independence. In 191 pre-frail older adults, higher FFMI was linked to better physical function, sharper cognition, and lower odds of being classified as sarcopenic. The ratio of fat mass to fat-free mass outperformed BMI as a predictor of these outcomes.
FFMI peaks in the mid-20s in men and the mid-40s in women, then declines, with steeper losses in men. This is why catching a downward trend in your forties or fifties is more useful than waiting for symptoms in your seventies.
FFMI varies substantially by age, sex, ethnicity, and the method used to measure it. The ranges below come from large adult cohorts using DXA or bioimpedance, and they are best used as orientation rather than rigid targets. Compare your results within the same lab and method over time.
| Population | Typical FFMI (men) | Typical FFMI (women) |
|---|---|---|
| UK adults 45 to 69 years | About 18 to 21 | About 15 to 18 |
| Italian adults 20 to 80 years (DEXA) | 18.7 to 21 (middle 50%) | 14.9 to 17.2 |
| Chinese adults | 18.6 (average) | 15.7 (average) |
Source: Franssen 2014 (UK Biobank), Coin 2008 (Italian DEXA cohort), Jin 2019 (Chinese adults).
For sarcopenia screening, widely used cutoffs are below 18 kg/m² for men and below 15 kg/m² for women in community adults. In Japanese older adults, refined cutoffs of 17.5 for men and 14.4 for women predicted falls. In esophageal cancer patients, low FFMI thresholds of 16.8 for men and 14.4 for women were associated with worse survival.
A single FFMI reading is a snapshot. The trend over years is the story. Adults lose lean mass slowly enough that you may not feel it, but the trajectory determines whether you will be physically robust in your seventies or struggling to climb stairs.
Get a baseline now, regardless of your age. If you are starting a strength training program, changing your protein intake, or beginning a weight-loss medication, retest in three to six months to confirm that you are gaining lean mass rather than losing it. After that, an annual reassessment is enough to catch a meaningful decline before it becomes clinically significant. Use the same method (DXA or the same BIA device) each time so the comparisons are valid.
If your FFMI is below typical thresholds for your sex, the response is not to wait. Pair the result with a grip strength measurement (a quick squeeze test of overall strength) and a fat mass index reading to determine whether you are dealing with low muscle alone, low muscle plus high fat (sarcopenic obesity), or whole-body undernutrition. A fall or unexplained weight loss in the past year, combined with a low FFMI, warrants a conversation with a clinician focused on geriatric medicine, oncology nutrition, or sports medicine, depending on context.
If your FFMI is high but your fat mass index is also high, the result reflects body size more than muscle quality. In that case, the next test to order is not another body composition scan but markers of metabolic health: fasting insulin, HbA1c (a measure of average blood sugar), and a lipid panel.
Evidence-backed interventions that affect your FFMI level
FFMI is best interpreted alongside these tests.